DE60021075D1 - Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika - Google Patents

Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika

Info

Publication number
DE60021075D1
DE60021075D1 DE60021075T DE60021075T DE60021075D1 DE 60021075 D1 DE60021075 D1 DE 60021075D1 DE 60021075 T DE60021075 T DE 60021075T DE 60021075 T DE60021075 T DE 60021075T DE 60021075 D1 DE60021075 D1 DE 60021075D1
Authority
DE
Germany
Prior art keywords
drugs
anticancer
resistance
anticancer drugs
carcinostatics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60021075T
Other languages
English (en)
Other versions
DE60021075T2 (de
Inventor
Noboru Kaneko
Kazuhito Nishio
Takashi Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60021075D1 publication Critical patent/DE60021075D1/de
Publication of DE60021075T2 publication Critical patent/DE60021075T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60021075T 1999-05-19 2000-05-19 Verwendung von 1,4-benzothiazepinderivaten als arzneimittel zur überwindung einer resistenz gegenüber einem arzneimittel gegen krebs Expired - Lifetime DE60021075T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP13919699 1999-05-19
JP13919699 1999-05-19
PCT/JP2000/003216 WO2000071132A1 (fr) 1999-05-19 2000-05-19 Utilisation de derives 1,4-benzothiazepine en tant que medicaments contre la tolerance cancerostatique

Publications (2)

Publication Number Publication Date
DE60021075D1 true DE60021075D1 (de) 2005-08-04
DE60021075T2 DE60021075T2 (de) 2006-05-24

Family

ID=15239803

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021075T Expired - Lifetime DE60021075T2 (de) 1999-05-19 2000-05-19 Verwendung von 1,4-benzothiazepinderivaten als arzneimittel zur überwindung einer resistenz gegenüber einem arzneimittel gegen krebs

Country Status (12)

Country Link
US (1) US6977252B1 (de)
EP (1) EP1184037B1 (de)
KR (1) KR100686617B1 (de)
CN (1) CN1178663C (de)
AT (1) ATE298575T1 (de)
AU (1) AU774656B2 (de)
CA (1) CA2373484C (de)
DE (1) DE60021075T2 (de)
NO (1) NO20015600L (de)
TW (1) TWI221093B (de)
WO (1) WO2000071132A1 (de)
ZA (1) ZA200109334B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
CN106795148B (zh) 2014-07-30 2019-12-10 埃塔斯制药株式会社 1,4-苯并硫氮杂*-1-氧化物衍生物的光学异构体及使用它的医药组合物
KR102440098B1 (ko) * 2020-07-31 2022-09-05 부산대학교 산학협력단 Agr2의 동종이량체를 표적으로 하는 저분자 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS579712A (en) * 1980-06-20 1982-01-19 Fukumi Morishige Instilling (dripping) liquid for intravenous injection
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
JP3093419B2 (ja) 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
JP4063964B2 (ja) 1998-08-12 2008-03-19 金子 昇 神経細胞保護薬

Also Published As

Publication number Publication date
DE60021075T2 (de) 2006-05-24
CA2373484A1 (en) 2000-11-30
EP1184037B1 (de) 2005-06-29
KR100686617B1 (ko) 2007-02-23
EP1184037A4 (de) 2003-12-03
WO2000071132A1 (fr) 2000-11-30
ATE298575T1 (de) 2005-07-15
AU4778300A (en) 2000-12-12
AU774656B2 (en) 2004-07-01
US6977252B1 (en) 2005-12-20
CA2373484C (en) 2009-01-20
NO20015600L (no) 2001-12-20
CN1178663C (zh) 2004-12-08
TWI221093B (en) 2004-09-21
KR20020008407A (ko) 2002-01-30
EP1184037A1 (de) 2002-03-06
NO20015600D0 (no) 2001-11-16
ZA200109334B (en) 2003-01-29
CN1361693A (zh) 2002-07-31

Similar Documents

Publication Publication Date Title
DE60119894D1 (de) Piperidinverbindungen und diese enthaltenden medikamente
ATE503746T1 (de) Neue imidazolidinderivate
HUP0302969A2 (hu) NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
KR960004344A (ko) 6원 질소 함유 헤테로아릴-옥사졸리디논
KR920000754A (ko) 환식아미드 유도체
DE69918404D1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
HUP0102793A2 (hu) Agydaganat kezelésére szolgáló kinazolinok és ezeket tartalmazó gyógyszerkészítmények
PT976748E (pt) Derivados de pirrolidina com actividade inibidora de fosfolipase a2
ES2164241T3 (es) Compuestos pentaciclicos.
CY1111816T1 (el) Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
IL154709A0 (en) Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same
DE60021075D1 (de) Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika
TR200101978T2 (tr) 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri.
DE69208400D1 (de) Mono- und Bis-Alkylaminoanthracycline
ATE261948T1 (de) 2-aminothiazol-kondensierte 2-aminoindane und 2- aminotetraline, sowie deren verwendung
HUP0002681A2 (hu) Endotelin antagonista hatású pirrolidin-karbonsav-származékok és ezeket tartalmazó gyógyszerkészítmények
ATE380799T1 (de) Biguanid-derivate und deren verwendung als antidiabetika
ATE234315T1 (de) Medikamente gegen trhombocytopenie
ATE493988T1 (de) Pyrimidinderivate enthaltendes medikament
BR0108448A (pt) Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor
KR910700252A (ko) 디아자비시클로알칸 유도체
TH36111A (th) อนุพันธ์ไพแรโซล

Legal Events

Date Code Title Description
8364 No opposition during term of opposition